Compare American Superconductor Corporation (AMSC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Superconductor Corporation vs Merck & Co., Inc. — how do they compare? American Superconductor Corporation trades at $35.2 (market cap $1.74B), while Merck & Co., Inc. trades at $123.56 (market cap $305.12B). The key difference: Merck & Co., Inc. is far larger — about 175.4× American Superconductor Corporation's market cap, and Merck & Co., Inc. pays a 2.75% dividend while American Superconductor Corporation pays none. Which is the better fit depends on your goals.
| AMSC | MRK | |
|---|---|---|
Market Cap | $1.74B | $305.12B |
Sector | Technology | Health |
52-Week High | $66.68 | $129.52 |
52-Week Low | $25.95 | $77.60 |
Enterprise Value | $1.61B | $348.54B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $35.96, down 3.26% today amid bearish technical signals. The stock shows strong fundamentals with recent earnings beats and robust profitability metrics including 44.73% net margin and 35.56% ROE. Revenue grew 34% year-over-year to $299.2 million in 2025, though cash flow trends show negative net cash flow of -$6.9M. Analyst sentiment remains positive with 53% buy ratings despite recent insider selling activity.
The outlook remains cautiously optimistic given strong order backlog growth of 40% and expanding role in AI energy infrastructure. Key risks include valuation concerns at 66.72x EV/EBITDA and acquisition-driven growth versus organic expansion. Earnings momentum and grid technology positioning provide upside potential if execution continues.
Merck (MRK) trades at $123.54, down 1.22% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $135.14. The company reported strong earnings beats in recent quarters, including Q1 2026, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, signaling strategic growth initiatives amid a competitive pharmaceutical landscape.
The stock presents a favorable risk-reward profile with upside potential driven by earnings momentum and strategic acquisitions, though risks include patent expirations and regulatory pressures. Institutional buying activity and a 67.57% buy rating from analysts underscore confidence, but investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
